NervGen Pharma Corp (NGEN) Stock AnalysisNGENNervGen Pharma Corp

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair. It operates in the Healthcare sector.

Nervgen Pharma Corp. is not a good buy right now. The current price is $1.35, which is significantly below the 52-week high of $6.30, indicating a steep decline of 78.40% year-to-date. Additionally, the RSI is at a very low 21.92, suggesting oversold conditions, but this may not be a strong enough signal to counteract the negative financial performance, including a net income loss of CAD 29,217,233 in Q2 2026. The main risk is the ongoing equity dilution from the recent public offering, which could further depress the stock price.